SDGR icon

Schrodinger

18.46 USD
-0.83
4.30%
Updated Jan 13, 11:52 AM EST
1 day
-4.30%
5 days
-12.51%
1 month
-11.38%
3 months
3.53%
6 months
-18.64%
Year to date
-9.51%
1 year
-32.65%
5 years
-35.54%
10 years
-35.54%
 

About: Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Employees: 787

0
Funds holding %
of 6,814 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

89% more call options, than puts

Call options by funds: $14.2M | Put options by funds: $7.55M

3% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 32

0% less funds holding

Funds holding: 205 [Q2] → 204 (-1) [Q3]

2.17% less ownership

Funds ownership: 96.87% [Q2] → 94.7% (-2.17%) [Q3]

6% less capital invested

Capital invested by funds: $1.19B [Q2] → $1.12B (-$72.3M) [Q3]

13% less repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 72

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$28
52%
upside
Avg. target
$28
52%
upside
High target
$28
52%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
BMO Capital
Gary Nachman
54% 1-year accuracy
7 / 13 met price target
52%upside
$28
Outperform
Maintained
13 Nov 2024

Financial journalist opinion

Neutral
Business Wire
4 hours ago
Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today provided an update on its progress across the business in 2024 and announced its strategic priorities for 2025. “We are very proud of our accomplishments in 2024. We advanced the capabilities of our computational platform and leveraged the synergies in our business, which included signing a multi-target research collaboration and expanded software licensing agreement with Novartis. We are pleased another innovative pharmaceutical.
Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities
Neutral
Business Wire
3 weeks ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on December 12, 2024, the company granted restricted stock units (RSUs) with respect to 8,365 shares of the company's common stock to six newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Neutral
Business Wire
1 month ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on November 14, 2024, the company granted restricted stock units (RSUs) with respect to 2,785 shares of the company's common stock to four newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducemen.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Neutral
Business Wire
1 month ago
Schrödinger Broadens and Accelerates Predictive Toxicology Initiative
NEW YORK--(BUSINESS WIRE)--Schrödinger broadens and accelerates predictive toxicology initiative.
Schrödinger Broadens and Accelerates Predictive Toxicology Initiative
Neutral
Seeking Alpha
2 months ago
Schrödinger (SDGR) Q3 2024 Earnings Call Transcript
Schrödinger Inc. (NASDAQ:SDGR ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Ramy Farid - President, Chief Executive Officer Karen Akinsanya - President, R&D and Therapeutics Geoff Porges - Chief Financial Officer Jaren Madden - Senior Vice President, Corporate Affairs and Investor Relations Conference Call Participants Matt - Jefferies Mani Foroohar - Leerink Partners Steve - Keybanc Gaspa - Morgan Stanley Evan Seigerman - BMO Capital Markets Joe Catanzaro - Piper Sandler Toff - Craig Hallum Brendan Smith - TD Cowen Sean Kim - Bank of America John - Citi Operator Welcome to Schrödinger's conference call to review our third quarter 2024 financial results. My name is Madison and I will be your Operator for today's call.
Schrödinger (SDGR) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
2 months ago
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.86 per share a year ago.
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates
Neutral
Business Wire
2 months ago
Schrödinger Reports Third Quarter 2024 Financial Results
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the third quarter of 2024 and provided a business update.
Schrödinger Reports Third Quarter 2024 Financial Results
Neutral
Business Wire
2 months ago
Schrödinger to Present at Jefferies London Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference.
Schrödinger to Present at Jefferies London Healthcare Conference
Neutral
Business Wire
2 months ago
Schrödinger to Announce Third Quarter 2024 Financial Results on November 12
NEW YORK--(BUSINESS WIRE)--Schrödinger will report its third quarter 2024 financial results on Tuesday, November 12, 2024, before the financial markets open.
Schrödinger to Announce Third Quarter 2024 Financial Results on November 12
Neutral
Business Wire
2 months ago
Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The data demonstrate that in preclinical models, treatment with SGR-3515 results in synergistic anti-tumor activity that leads to deeper and more durable responses compared to inhibitors that target only Wee1 or Myt1. The preclinical data also show that SGR-3515 has a favorable ph.
Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium
Charts implemented using Lightweight Charts™